ImmuneBridge
IMMUNEBRIDGE - Bridging to large national adaptive population-based panels to generate data on SARS-CoV-2 population immunity correlates in 2022 in Germany
The aim of Immunebridge is to derive estimates of protection levels against SARS CoV-2 infection and severe COVID-19 in the German general population. This will be done by bringing together established large population-based cohorts with newly designed cross-sectional studies by using central data linkage structures, targeted literature synthesis, and central laboratory infrastructure, to allow the preparation of action plans for winter 2022/23. The data collected should close knowledge gaps, provide more comprehensive information for analyses and estimates of the future course of the pandemic and provide further insights into inpatient care for COVID-19.
Lange, B., Jäger, V., Rücker, V., Hassenstein, M., Harries, M., Berner, R., … Karch, A. Interimsanalyse des IMMUNBRIDGE-Projektes zur Kommunikation von vorläufigen Ergebnissen an die Modellierungskonsortien der BMBF-geförderten Modellierungsplattform. Zenodo. 08.08.2022. https://zenodo.org/record/6968574#.YygfsXZBwuU
Lange, B., Jäger, V., Rücker, V., Hassenstein, M., Harries, M., Berner, R., … Karch, A. 2. Interimsanalyse des IMMUNBRIDGE-Projektes zur Kommunikation von vorläufigen Ergebnissen an das Modellierungsnetz für schwere Infektionskrankheiten. Zenodo. 12.10.2022. https://zenodo.org/record/7177592#.Y00D4HZBxaR
Schulze-Wundling, K., Ottensmeyer, P., Meyer-Schlinkmann, K., Deckena, M., Krüger, S., Schlinkert, S., Budde, A., Münstermann, D., Töpfner, N., Petersmann, A., Nauck, M., Karch, A., Lange, B., Blaschke, S., Tiemann, C., Streeck, H.. Grundimmunität gegen SARS-CoV-2 in der deutschen Bevölkerung. 06.04.2023. https://www.aerzteblatt.de/archiv/230671/Grundimmunitaet-gegen-SARS-CoV-2-in-der-deutschen-Bevoelkerung
Lange B, Jaeger VK, Harries M, Rücker V, Streeck H, Blaschke S, Petersmann A, Toepfner N, Nauck M, Hassenstein MJ, Dreier M, von Holt I, Budde A, Bartz A, Ortmann J, Kurosinski MA, Berner R, Borsche M, Brandhorst G, Brinkmann M, Budde K, Deckena M, Engels G, Fenzlaff M, Härtel C, Hovardovska O, Katalinic A, Kehl K, Kohls M, Krüger S, Lieb W, Meyer-Schlinkmann KM, Pischon T, Rosenkranz D, Rübsamen N, Rupp J, Schäfer C, Schattschneider M, Schlegtendal A, Schlinkert S, Schmidbauer L, Schulze-Wundling K, Störk S, Tiemann C, Völzke H, Winter T, Klein C, Liese J, Brinkmann F, Ottensmeyer PF, Reese JP, Heuschmann P, Karch A. Estimates of protection levels against SARS-CoV-2 infection and severe COVID-19 in Germany before the 2022/2023 winter season: the IMMUNEBRIDGE project. Infection. 2024 Feb;52(1):139-153. doi: 10.1007/s15010-023-02071-2.
Engels G, Oechsle AL, Schlegtendal A, Maier C, Holzwarth S, Streng A, Lange B, Karch A, Petersmann A, Streeck H, Blaschke-Steinbrecher S, Härtel C, Schroten H, von Kries R, Berner R, Liese J, Brinkmann F, Toepfner N; IMMUNEBRIDGE KIDS study group. SARS-CoV-2 sero-immunity and quality of life in children and adolescents in relation to infections and vaccinations: the IMMUNEBRIDGE KIDS cross-sectional study, 2022. Infection. 2023 Oct;51(5):1531-1539. doi: 10.1007/s15010-023-02052-5.
Project details
Responsible persons
Status
Finished
Cooperation partners
Helmholtz Centre for Infection Research (HZI)
Institute of Clinical Epidemiology and Biometry, Julius-Maximilians-Universität Würzburg
Institute of Virology, Medical Faculty, University of Bonn
Emergency Department, University Medical Center Göttingen
Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Oldenburg
Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald
Department of Pediatrics, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden
DZHK (German Centre for Cardiovascular Research), Partner Site Greifswald, University Medicine Greifswald
Institute for Epidemiology, Social Medicine and Health Systems Research, Hannover Medical School
Institute of Neurogenetics, University of Lübeck
MVZ Labor Krone GbR, Bad Salzuflen, Germany
Department of Pediatrics, University Hospital Würzburg
Institute of Social Medicine and Epidemiology, University of Luebeck
Dimap, das Institut Für Markt- Und Politikforschung GmbH, Bonn, Germany
Institute of Epidemiology, Christian-Albrechts-University of Kiel
Molecular Epidemiology Research Group, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
Department of Infectious Diseases and Microbiology, University Hospital Schleswig-Holstein, German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Lübeck, Germany
University Children’s Hospital, Ruhr University Bochum
Department of Internal Medicine I, University Hospital Würzburg
Institute for Community Medicine, University Medicine Greifswald
Funding
BMBF via Netzwerk Universitätsmedizin (NUM)
Lange, B., Jäger, V., Rücker, V., Hassenstein, M., Harries, M., Berner, R., … Karch, A. Interimsanalyse des IMMUNBRIDGE-Projektes zur Kommunikation von vorläufigen Ergebnissen an die Modellierungskonsortien der BMBF-geförderten Modellierungsplattform. Zenodo. 08.08.2022. https://zenodo.org/record/6968574#.YygfsXZBwuU
Lange, B., Jäger, V., Rücker, V., Hassenstein, M., Harries, M., Berner, R., … Karch, A. 2. Interimsanalyse des IMMUNBRIDGE-Projektes zur Kommunikation von vorläufigen Ergebnissen an das Modellierungsnetz für schwere Infektionskrankheiten. Zenodo. 12.10.2022. https://zenodo.org/record/7177592#.Y00D4HZBxaR
Schulze-Wundling, K., Ottensmeyer, P., Meyer-Schlinkmann, K., Deckena, M., Krüger, S., Schlinkert, S., Budde, A., Münstermann, D., Töpfner, N., Petersmann, A., Nauck, M., Karch, A., Lange, B., Blaschke, S., Tiemann, C., Streeck, H.. Grundimmunität gegen SARS-CoV-2 in der deutschen Bevölkerung. 06.04.2023. https://www.aerzteblatt.de/archiv/230671/Grundimmunitaet-gegen-SARS-CoV-2-in-der-deutschen-Bevoelkerung
Lange B, Jaeger VK, Harries M, Rücker V, Streeck H, Blaschke S, Petersmann A, Toepfner N, Nauck M, Hassenstein MJ, Dreier M, von Holt I, Budde A, Bartz A, Ortmann J, Kurosinski MA, Berner R, Borsche M, Brandhorst G, Brinkmann M, Budde K, Deckena M, Engels G, Fenzlaff M, Härtel C, Hovardovska O, Katalinic A, Kehl K, Kohls M, Krüger S, Lieb W, Meyer-Schlinkmann KM, Pischon T, Rosenkranz D, Rübsamen N, Rupp J, Schäfer C, Schattschneider M, Schlegtendal A, Schlinkert S, Schmidbauer L, Schulze-Wundling K, Störk S, Tiemann C, Völzke H, Winter T, Klein C, Liese J, Brinkmann F, Ottensmeyer PF, Reese JP, Heuschmann P, Karch A. Estimates of protection levels against SARS-CoV-2 infection and severe COVID-19 in Germany before the 2022/2023 winter season: the IMMUNEBRIDGE project. Infection. 2024 Feb;52(1):139-153. doi: 10.1007/s15010-023-02071-2.
Engels G, Oechsle AL, Schlegtendal A, Maier C, Holzwarth S, Streng A, Lange B, Karch A, Petersmann A, Streeck H, Blaschke-Steinbrecher S, Härtel C, Schroten H, von Kries R, Berner R, Liese J, Brinkmann F, Toepfner N; IMMUNEBRIDGE KIDS study group. SARS-CoV-2 sero-immunity and quality of life in children and adolescents in relation to infections and vaccinations: the IMMUNEBRIDGE KIDS cross-sectional study, 2022. Infection. 2023 Oct;51(5):1531-1539. doi: 10.1007/s15010-023-02052-5.